Charles River - JP Morgan Conference Presentation
Large and diverse client base provides
stability and sustained growth
Most of top 25 clients are large biopharmaceutical companies
Capital market dependent (CMD) public biotechs with <2 years cash represent
only ~5% of revenue
Strong client overlap between business segments with opportunity to further capture
incremental client wallet share
Revenue by
Client Segment*
CRL New Biotech
Clients Added
>2.000
Biopharma clients in 2022
Largest client
~3%
of total
YTD 3Q22 revenue
-20%
-10%
419
410
410
■ Biotech
~40%
■ Globals
■ Other
-30%
■ Academic/
Government
Charles River - JP Morgan Conference Presentation
485
2019 2020 2021 YTD
3Q22
Note: CRL revenue by client segment based on LTM September 2022 revenue.
Top 25 clients
-30%
of total
YTD 3Q22 revenue
19View entire presentation